We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Pharmacyclics has announced the publication of interim data from a Phase II
clinical trial of Xcytrin (motexafin gadolinium) injection, the company's lead
anticancer agent, for the treatment of patients with advanced, recurrent renal
cell carcinoma.
Adventrx Pharmaceuticals has announced a 63 percent overall clinical benefit
and a 38 percent objective response rate in measurable patients treated with
CoFactor and 5-fluorouracil (5-FU) as a first-line treatment of metastatic colorectal
cancer in its Phase II trial.
Point Therapeutics has presented positive results in the company's Phase II
study of talabostat in combination with docetaxel in patients with advanced
non-small cell lung cancer (NSCLC).
SuperGen has reported results from a Phase III study of Orathecin versus 5-FU
in pancreatic cancer patients with progressive disease following treatment with
gemcitabine.
BioMarin Pharmaceutical and Serono have formed a strategic alliance for the
further development and commercialization of two BioMarin product candidates,
Phenoptin (sapropterin HCl) and Phenylase (phenylalanine ammonia lyase).
CEL-SCI scientists, in collaboration with scientists from the laboratory of
Noel Rose at The Johns Hopkins University Department of Pathology, has presented
animal data showing that pretreatment and early therapy of Experimental Autoimmune
Myocarditis with a compound developed by CEL-SCI resulted in significant reduction
in heart enlargement and disease associated histopathological changes.
Hemispherx Biopharma has initiated clinical trials as part of an accelerated
evaluation of the experimental biotherapeutic Alferon LDO (Low Dose Oral Interferon
Alfa-n3 (Human Leukocyte Derived)) as a potential new experimental therapy for
Avian Flu and other lethal viral diseases, which have high acute death rates.
Sonus Pharmaceuticals has reported the results of a clinical pharmacology study,
showing that a single 175 mg/m2 dose of Tocosol Paclitaxel, the company's novel
paclitaxel product, administered over 15 minutes delivered 67 percent more active
paclitaxel into the circulation over time compared to an identical dose of Taxol
given over three hours.
ZymoGenetics has announced that an oral presentation and two posters concerning
Interleukin 21 (IL-21), a potential treatment for cancer, were given at the
recent American Society of Clinical Oncology 2005 annual meeting.
OXiGENE has announced that a clinical investigator studying the company's lead
vascular targeting agent, Combretastatin A4 Prodrug (CA4P), has noted that CA4P
is well-tolerated when combined with radiotherapy thus far in the Phase Ib portion
of a planned Phase Ib/II combination trial of the compound in patients with
advanced cancer.